Malignant Melanoma | Current Treatment: Physician Insights | US | 2017
The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune checkpoint inhibitors (ICIs) and BRAF/MEK-targeted therapies have changed the treatment landscape dramatically. Combination therapies are playing an increasingly greater role in the unresectable recurrent or metastatic setting, including regimens such as Novartis’s Tafinlar plus Mekinist (2014), Roche/Genentech’s Zelboraf plus Cotellic (2015), and Bristol-Myers Squibb’s Opdivo plus Yervoy (2015). Consequently, optimizing sequencing decisions is a key focus for prescribing oncologists, irrespective of patients’ BRAF mutation status.
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
